Kaposi's sarcoma

(redirected from Kaposi Sarcoma)
Also found in: Dictionary, Thesaurus, Medical.

Kaposi's sarcoma

(käp`əshē', kəpō`sē), a usually fatal cancer that was considered rare until its appearance in AIDSAIDS
or acquired immunodeficiency syndrome,
fatal disease caused by a rapidly mutating retrovirus that attacks the immune system and leaves the victim vulnerable to infections, malignancies, and neurological disorders. It was first recognized as a disease in 1981.
..... Click the link for more information.
 patients. First described by an Austro-Hungarian physician, Moritz Kaposi, in 1872, it appears in three forms and is characterized by vascular skin tumors. Kaposi's sarcoma is endemic in Africa, where it is more aggressive, seen in children and young men, and accounts for 10% of malignancies in Congo (Kinshasa) and Uganda. A mild form of the disease is sometimes seen in elderly men of Mediterranean origin. The development of AIDS-related Kaposi's sarcoma has been linked to a virus of the herpes group. In the early 1980s it was seen in nearly 50% of AIDS patients, but the proportion has decreased since that time. In AIDS, Kaposi's presents as barely raised pink or red papules or plaques that become widely disseminated on the skin and in the gastrointestinal and respiratory tracts, where they may cause extensive bleeding. Treatment includes chemotherapy or surgical excision, cryosurgury (destruction by freezing), or electrodessication (destruction by heat). Local radiation therapy can also be effective. AIDS patients are treated with Vinblastine, an active, but weak, agent, which further lowers immunity.

Kaposi's sarcoma

[kə′pō·sēz sär′kōm·ə]
(medicine)
A multifocal malignant or benign neoplasm that occurs in the skin and sometimes in lymph nodes or viscera and is composed of primitive tissue that is involved in blood vessel formation.
References in periodicals archive ?
The encouraging news of the FDA Breakthrough Therapy designation for POMALYST in Kaposi sarcoma reflects the urgency in accelerating the development of therapies to address diseases of this type, said Jay Backstrom, M.D., Chief Medical Officer for Celgene.
Although the use of combination anti-retroviral treatments (cART or HAART) has reduced the incidence of advanced Kaposi sarcoma in the United States, there are still nearly 2000 new cases each year.
Kaposi sarcoma rewiew and medical management update.
Spindle cell tumors associated with mycobacteria in lymph nodes of HIV-positive patients: 'Kaposi sarcoma with mycobacteria' and 'mycobacterial pseudotumor'.
They sketched a disease roadmap for a soft tissue cancer called Kaposi sarcoma.
Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment: spontaneous regression 8 months after discontinuing therapy.
Kaposi sarcoma accounts for 5.7%-ll% of all neoplasms arising after KT (33,34).
The report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
It has various synonyms, such as acroangiodermatitis of Mali-Kuiper, gravitational purpura, stasis purpura, acral capillary angiomatosis and pseudo Kaposi sarcoma. (2) Mali et al.
Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol.